Actimab-A is a humanized anti-CD33 antibody conjugated to Actinium-225 (Ac-225). With its potent alpha-particle payload ...

In March 2025, Akeso initiated an open-label, Phase Ib/II study involving patients diagnosed with acute myeloid leukemia (AML ...

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad ...

Acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) are blood cell cancers that start in the bone marrow. AML is more common and more aggressive than CML. AML is usually treated with ...

An acute stroke, like most forms of stroke, starts suddenly and worsens rapidly. Some strokes may be preceded by a transient ischemic attack (TIA), a temporary stroke that resolves before causing any ...

However, these advances are not uniform across the world. In the case of patients with acute myeloid leukaemia (AML), an aggressive form of blood cancer, these advances only reach a miniscule ...

Medicare plans include benefits that can help with leukemia treatment costs. Out-of-pocket expenses may apply, and additional support may be available. Medicare covers many of the costs of care ...

CHICAGO, ILLINOIS / ACCESS Newswire / February 17, 2025 / The American Society for Transplantation and Cellular Therapy ® (ASTCT ®) is pleased to announce David L. Porter, MD, as the Society's ...

For example, investigational agents undergoing development for use in AML include FLT3 inhibitors, polo-like kinase inhibitors, farnesyltransferase inhibitors, HSP90 inhibitors, Mdm2 inhibitors ...

Prognostic gene expression signatures have been proposed as clinical tools to clarify therapeutic options in acute myeloid leukemia (AML). However, these signatures rely on measuring large numbers ...

allowing a reduced Phase 3 trial size for Annamycin with Cytarabine also known as AnnAraC in treating R/R AML patients. The global "MIRACLE" trial will span the US, Europe, and the Middle East.